

**Amendments to the Claims**

Please add new Claims 111-146. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1-74. Canceled

75. (Previously presented) An antibody or antigen binding fragment thereof which binds to a mammalian chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor and inhibits one or more functions associated with binding of the chemokine to the receptor.
76. (Previously presented) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment has specificity for mammalian chemokine receptor 5 (CCR5).
77. (Previously presented) The antibody or antigen binding fragment thereof of Claim 75, wherein the mammalian chemokine receptor 5 (CCR5) is a human chemokine receptor 5 (CCR5).
78. (Previously presented) The antibody or antigen binding fragment thereof of Claim 75, wherein the chemokine is selected from the group consisting of MIP-1 $\alpha$ , MIP-1 $\beta$  and RANTES or a combination thereof.
79. (Previously presented) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.
80. (Previously presented) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.

81. (Previously presented) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.
82. (Previously presented) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.
83. (Previously presented) The antibody or antigen binding fragment thereof of Claim 82, wherein the humanized antibody comprises at least six complementarity determining regions of a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 and a portion of an immunoglobulin of human origin.
84. (Previously presented) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment binds the second extracellular loop of mammalian chemokine receptor 5 (CCR5).
85. (Previously presented) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).
86. (Previously presented) The antibody or antigen binding fragment thereof of Claim 75, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')<sub>2</sub> fragment.
87. (Previously presented) A composition comprising an antibody or antigen binding fragment thereof which binds to a mammalian chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor and inhibits one or more functions associated with binding of the chemokine to the receptor.

88. (Previously presented) The composition of Claim 87, wherein the antibody or antigen binding fragment has specificity for mammalian chemokine receptor 5 (CCR5).
89. (Previously presented) The composition of Claim 87, wherein the mammalian chemokine receptor 5 (CCR5) is a human chemokine receptor 5 (CCR5).
90. (Previously presented) The composition of Claim 87, wherein the chemokine is selected from the group consisting of MIP-1 $\alpha$ , MIP-1 $\beta$  and RANTES or a combination thereof.
91. (Previously presented) The composition of Claim 87, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.
92. (Previously presented) The composition of Claim 87, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.
93. (Previously presented) The composition of Claim 87, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.
94. (Previously presented) The composition of Claim 87, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.
95. (Previously presented) The composition of Claim 94, wherein the humanized antibody comprises at least six complementarity determining regions of a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 and a portion of an immunoglobulin of human origin.
96. (Previously presented) The composition of Claim 87, wherein the antibody or antigen binding fragment binds the second extracellular loop of mammalian chemokine receptor 5 (CCR5).
97. (Previously presented) The composition of Claim 87, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma

deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).

98. (Previously presented) The composition of Claim 87, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')<sub>2</sub> fragment.
99. (Previously presented) A test kit for use in detecting the presence of a mammalian chemokine receptor 5 (CCR5) in a biological sample comprising:
  - a) an antibody or antigen binding fragment thereof which binds to a mammalian chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor and inhibits one or more functions associated with binding of the chemokine to the receptor; and
  - b) one or more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen binding fragment and said receptor.
100. (Previously presented) The test kit of Claim 99, wherein the antibody or antigen binding fragment has specificity for mammalian chemokine receptor 5 (CCR5).
101. (Previously presented) The test kit of Claim 99, wherein the mammalian chemokine receptor 5 (CCR5) is a human chemokine receptor 5 (CCR5).
102. (Previously presented) The test kit of Claim 99, wherein said chemokine is selected from the group consisting of MIP-1 $\alpha$ , MIP-1 $\beta$  and RANTES or a combination thereof.
103. (Previously presented) The test kit of Claim 99, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.
104. (Previously presented) The test kit of Claim 99, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.

105. (Previously presented) The test kit of Claim 99, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.
106. (Previously presented) The test kit of Claim 99, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.
107. (Previously presented) The test kit of Claim 106, wherein the humanized antibody comprises at least six complementarity determining regions of a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 and a portion of an immunoglobulin of human origin.
108. (Previously presented) The test kit of Claim 99, wherein the antibody or antigen binding fragment binds the second extracellular loop of mammalian chemokine receptor 5 (CCR5).
109. (Previously presented) The test kit of Claim 99, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).
110. (Previously presented) The test kit of Claim 99, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')<sub>2</sub> fragment.
111. (New) An antibody or antigen binding fragment thereof which binds to a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is selected from the group consisting of MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment thereof inhibits one or more functions associated with binding of the chemokine to the receptor.
112. (New) The antibody or antigen binding fragment of Claim 75, wherein said antibody or antigen binding fragment inhibits HIV infection.

113. (New) The antibody or antigen binding fragment of Claim 76, wherein said antibody or antigen binding fragment inhibits HIV infection.
114. (New) The antibody or antigen binding fragment of Claim 77, wherein said antibody or antigen binding fragment inhibits HIV infection.
115. (New) The antibody or antigen binding fragment of Claim 78, wherein said antibody or antigen binding fragment inhibits HIV infection.
116. (New) The antibody or antigen binding fragment of Claim 79, wherein said antibody or antigen binding fragment inhibits HIV infection.
117. (New) The antibody or antigen binding fragment of Claim 80, wherein said antibody or antigen binding fragment inhibits HIV infection.
118. (New) The antibody or antigen binding fragment of Claim 81, wherein said antibody or antigen binding fragment inhibits HIV infection.
119. (New) The antibody or antigen binding fragment of Claim 82, wherein said antibody or antigen binding fragment inhibits HIV infection.
120. (New) The antibody or antigen binding fragment of Claim 83, wherein said antibody or antigen binding fragment inhibits HIV infection.
121. (New) The antibody or antigen binding fragment of Claim 84, wherein said antibody or antigen binding fragment inhibits HIV infection.
122. (New) The antibody or antigen binding fragment of Claim 86, wherein said antibody or antigen binding fragment inhibits HIV infection.
123. (New) The composition of Claim 87, wherein the antibody or antigen binding fragment inhibits HIV infection.

124. (New) The composition of Claim 88, wherein the antibody or antigen binding fragment inhibits HIV infection.
125. (New) The composition of Claim 89, wherein the antibody or antigen binding fragment inhibits HIV infection.
126. (New) The composition of Claim 90, wherein the antibody or antigen binding fragment inhibits HIV infection.
127. (New) The composition of Claim 91, wherein the antibody or antigen binding fragment inhibits HIV infection.
128. (New) The composition of Claim 92, wherein the antibody or antigen binding fragment inhibits HIV infection.
129. (New) The composition of Claim 93, wherein the antibody or antigen binding fragment inhibits HIV infection.
130. (New) The composition of Claim 94, wherein the antibody or antigen binding fragment inhibits HIV infection.
131. (New) The composition of Claim 95, wherein the antibody or antigen binding fragment inhibits HIV infection.
132. (New) The composition of Claim 96, wherein the antibody or antigen binding fragment inhibits HIV infection.
133. (New) The composition of Claim 98, wherein the antibody or antigen binding fragment inhibits HIV infection.
134. (New) The test kit of Claim 99, wherein the antibody or antigen binding fragment inhibits HIV infection.

135. (New) The test kit of Claim 100, wherein the antibody or antigen binding fragment inhibits HIV infection.
136. (New) The test kit of Claim 101, wherein the antibody or antigen binding fragment inhibits HIV infection.
137. (New) The test kit of Claim 102, wherein the antibody or antigen binding fragment inhibits HIV infection.
138. (New) The test kit of Claim 103, wherein the antibody or antigen binding fragment inhibits HIV infection.
139. (New) The test kit of Claim 104, wherein the antibody or antigen binding fragment inhibits HIV infection.
140. (New) The test kit of Claim 105, wherein the antibody or antigen binding fragment inhibits HIV infection.
141. (New) The test kit of Claim 106, wherein the antibody or antigen binding fragment inhibits HIV infection.
142. (New) The test kit of Claim 107, wherein the antibody or antigen binding fragment inhibits HIV infection.
143. (New) The test kit of Claim 108, wherein the antibody or antigen binding fragment inhibits HIV infection.
144. (New) The test kit of Claim 110, wherein the antibody or antigen binding fragment inhibits HIV infection.
145. (New) The antibody or antigen binding fragment of Claim 111, wherein said antibody or antigen binding fragment inhibits HIV infection.



146. (New) An antibody or antigen binding fragment thereof which binds to a human chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor, wherein said chemokine is selected from the group consisting of MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES, or a combination thereof, and wherein said antibody or antigen binding fragment thereof inhibits one or more functions associate with binding of the chemokine to the receptor, and inhibits HIV infection.